Oncology

Latest News

The findings suggest that inhibition of midkine might be a meaningful tool to improve treatment outcomes in SCLC. | Image credit: Pixel-Shot - stock.adobe.com

July 24th 2025

New data show midkine expression is heightened in small cell lung cancer, suggesting the growth factor may be an important therapeutic target.

The FDA has issued a complete response letter for RP1 plus nivolumab for advanced melanoma after a PD-1 inhibitor–containing regimen. | Image credit: ra2studio - stock.adobe.com

RP1 Plus Nivolumab Receives CRL for Advanced Melanoma

By Chris Ryan

July 24th 2025

David Nguyen, MD | Image Credit: Tufts Medicine

It Take a Village in Cancer Care: A Q&A With David Nguyen, MD

By Maggie L. Shaw
David Nguyen, MD

July 23rd 2025

In Data Race, Flatiron Health Touts Tripling of Global Oncology Research Network

By Mary Caffrey

July 23rd 2025

Emerging therapies, including immune checkpoint inhibitors and antibody-drug conjugates, could significantly impact SCLC treatment, authors of a recent review concluded. | Image credit: Vitalii Vodolazskyi - stock.adobe.com

Is a New Era of SCLC, LCNEC Treatments on the Horizon?

By AJMC Contributor

July 23rd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

July 29th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 29th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

February 24th 2021

Oncolytic Virus, CAR T Combination Preclinical Study Shows Activity in Solid Tumors

Rose McNulty

Loading chimeric antigen receptor (CAR) T-cells with the oncolytic virus pelareorep improved their efficacy in solid tumor mouse models in a preclinical study presented at the CAR-TCR Summit Europe 2021.

February 24th 2021

Real-World Outcomes Contrast Cancer Clinical Trial Results in Medicare Patients

Rose McNulty

Pivotal cancer clinical trial data may lack generalizability in older adults with Medicare, a study published online today in JAMA Network Open found.

FDA Approves Libtayo Monotherapy for First-Line Advanced NSCLC With PD-L1 Expression

February 22nd 2021

FDA Approves Cemiplimab for First-Line Advanced NSCLC With PD-L1 Expression

Rose McNulty

The PD-1 inhibitor cemiplimab-rwlc, sold as Libtayo, was FDA approved as a monotherapy for patients with first-line advanced non–small cell lung cancer (NSCLC) with PD-L1 expression of at least 50%.

February 18th 2021

Use of COTA Nodal Address Highlights Variance in Cancer Care Cost: An Interview With Donald M. Berwick, MD, MPP

Mary Caffrey

Donald M. Berwick, MD, MPP, the former CMS administrator who is president emeritus and senior fellow at the Institute for Healthcare Improvement, discusses cost variation in cancer care found through the digital classification system the COTA Nodal Address.

February 18th 2021

Radiation Oncology’s Role in the Next Chapter of Payment Reform

Anne Hubbard, MBA

An ideal alternative payment model would reward radiation oncologists for participation in a value-based payment arrangement that grants them the freedom to make care delivery decisions based on patient needs and in accordance with clinical guidelines, says ASTRO's Anne Hubbard, MBA.

February 17th 2021

Cosela Approved for Protection Against Myelosuppression From SCLC Treatment

Maggie L. Shaw

The cyclin-dependent kinase 4/6 inhibitor trilaciclib (Cosela) is the first in its class to receive FDA approval as a protective agent against bone marrow loss from treatment for small cell lung cancer (SCLC).

Amy Ellis, Northwest Medical Specialties

February 17th 2021

Amy Ellis: There Was a Big Shift to Telemedicine in Cancer Care Delivery

With the onset of the pandemic, the increased use of telemedicine has been the biggest change to how cancer care is being delivered; however, whether telemedicine is here to stay depends on the regulators and payers, said Amy Ellis, chief quality officer at Northwest Medical Specialties.

February 16th 2021

Flying the Plane While You Build It

Joseph Alvarnas, MD

In this issue of Evidence-Based Oncology™ we see a foreshadowing of what the future of cancer care innovation could look like and how we may learn to move forward, safely, at an ever-accelerating pace.

February 10th 2021

Liquid Biopsy Demonstrates Clinical Utility in Advanced Prostate Cancer

Rose McNulty

A new study assessed the genomic alterations identified by ctDNA analysis compared with tissue-based comprehensive genomic profiling in patients with metastatic castration-resistant prostate cancer.

February 3rd 2021

Amy Ellis on the Benefits of ePROs in Cancer Care

Electronic patient-reported outcomes (ePROs) tools can benefit patients by keeping them on treatment longer, and the pandemic has likely accelerated how many practices move to using ePROs, said Amy Ellis, chief quality officer at Northwest Medical Specialties.

January 22nd 2021

Amy Ellis Discusses Setting Up an ePRO Tool at a Community Cancer Center

Setting up a new tool to capture electronic patient-reported outcomes (ePROs) requires a lot of prep work to ensure patients are comfortable and ready to use the tool, said Amy Ellis, chief quality officer at Northwest Medical Specialties.

Sibel Blau, MD, Northwest Medical Specialties, Quality Cancer Care Alliance

January 18th 2021

Dr Sibel Blau Discusses Adapting to Telehealth in Oncology and Future Issues

Adapting to telehealth was not difficult, but practice transformation around telehealth has been more difficult, and there remains the future uncertainty around continued reimbursement, said Sibel Blau, MD, of Northwest Medical Specialties and Quality Cancer Care Alliance.

January 12th 2021

Dr Sibel Blau Discusses the Impact of Delayed Cancer Diagnoses on Community Cancer Practices

Telehealth is helpful, but it is not enough to make up for the delay in cancer diagnoses occurring as a result of the pandemic, said Sibel Blau, MD, of Northwest Medical Specialties and Quality Cancer Care Alliance.

January 8th 2021

What We’re Reading: AHA Wants Faster Vaccine Rollout; Cancer Effect on Hearts; Teen Opioid Access

AJMC Staff

The American Hospital Association (AHA) asks HHS Secretary Alex Azar to expedite the rollout of coronavirus disease 2019 vaccines; CDC data show accelerated cardiac aging among cancer survivors; a study examines new targets for reducing adolescent access to opioids.

January 6th 2021

Dr Basit Chaudhry Expects CMS to Take Feedback From the Field to Improve OCF

Feedback from the field is incredibly important when participating in new payment models like the Oncology Care Model, said Basit Chaudhry, MD, PhD, founder of Tuple Health.

December 28th 2020

The Top 5 Most-Read Oncology Stories of 2020

Rose McNulty

Our 5 most-read oncology stories and most-watched videos this year highlighted cancer care policy, diversity, and the growing practice of remote cancer care.

December 26th 2020

Mike Fazio on Choosing Between Oncology Care First or Another Oncology APM

Practices deciding whether to join Oncology Care First or another oncology alternative payment model (APM) will need a clear understanding of how big of a transformation they’ll need to make to their practice, said Mike Fazio.

December 24th 2020

Radiopharmaceuticals Are Showing Promise as the Next Generation of Cancer Treatment

JT Ripton

Recent major investments signal growth in an emerging therapeutic sector.

December 21st 2020

COA Continues Effort to Stop Most Favored Nation Model

Rose McNulty

The Community Oncology Alliance's request includes declarations from community oncology practices detailing the anticipated ramifications should the Most Favored Nation rule become operative.

December 15th 2020

Kashyap Patel, MD, Elected President of Community Oncology Alliance

Rose McNulty

Kashyap Patel, MD, associate editor of Evidence-Based Oncology, a publication of The American Journal of Managed Care, will serve a 1-year term beginning in January.

December 14th 2020

Dr Basit Chaudhry: How Practices Can Take Advantage of the Delay to Oncology Care First

With the start of Oncology Care First (OCF) being delayed, practices participating in the Oncology Care Model have more time to set themselves up to success when they transition to OCF, said Basit Chaudhry, MD, PhD, founder of Tuple Health.

December 9th 2020

Mike Fazio Discusses Data Lag Challenges in OCM and OCF

Throughout the Oncology Care Model (OCM), practices have dealt with a data lag, but in Oncology Care First (OCF) data is expected to be released more frequently, said Mike Fazio, of Archway Health.

December 8th 2020

ASCO Releases Recommendations for Postpandemic Cancer Care

Rose McNulty

The American Society of Clinical Oncology calls on government bodies and the health care community to guide the cancer community’s post-pandemic recovery.

December 3rd 2020

AYA Cancer Rates Are Rising, New Study Finds

Rose McNulty

A new study published in JAMA Network Open found that the rate of cancer in adolescents and young adults increased by nearly 30% from 1973 to 2015.

Sara L. Douglas, PhD, RN, Frances Payne Bolton School of Nursing, Case Western Reserve University

December 3rd 2020

Dr Sara Douglas: Support Is Often Hard to Come By for Distance Caregivers

Distance caregivers of patients with cancer often find it difficult to enlist adequate support, noted Sara L. Douglas, PhD, RN, associate dean for research at the Frances Payne Bolton School of Nursing at Case Western Reserve University.

Randall Oyer, MD, president of the Association of Community Cancer Centers

November 24th 2020

Dr Randall Oyer on ACCC and ASCO's Work to Reduce Clinical Trial Disparities

Rose McNulty

Randall Oyer, MD, president of the Association of Community Cancer Centers, discusses the ACCC and American Society of Clinical Oncology's initiative to make clinical trials more inclusive.

November 20th 2020

How US Oncology Network Practices Find Success in the OCM

Rose McNulty

The Network enrolled its 100,000th patient in the Oncology Care Model (OCM) recently, and its practices are finding success in the complicated model.

November 17th 2020

Dr Karen Winkfield Discusses Importance of Workforce Diversity in Oncology

Representation of minority populations in the oncology workforce is important to educate physicians on the meaning of being culturally appropriate, and to provide culturally appropriate care.

November 12th 2020

Medicaid Expansion Associated With More Early-Stage Cancer Diagnoses

Rose McNulty

Data in a new analysis showed that Medicaid expansion under the Affordable Care Act had positive effects on rates of early-stage cancer diagnosis, and the results were immediate.

David Jackman, MD, Dana-Farber Cancer Institute

November 10th 2020

Dr David Jackman on Clinical Pathway Buy-in, Update Process

Efficiency, collaboration, and efficacy are key drivers in creating clinical pathway buy-in, with updates also vital to incorporate the latest trends and insights in cancer care.

...

17 18 19 20 21 22 23 24 25

...

187 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions